A phase Ib/II, open-label, multicentric study evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation.
Fase: Phase II-III clinical trials
Principal Investigator: Prof. De Braud Filippo
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: Divarasib, Pembrolizumab, Chemotherapy
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC) With a KRAS G12C Mutation.
If you decide to participate in the trial, you will be placed in one of two treatment groups and will be able to receive:
- Group A: divarasib + pembrolizumab
- Group B: divarasib + pembrolizumab and chemotherapy
Last update: 20/05/2025